Business Context and Reporting Period
This Form 8-K was filed by Cormedix Inc. on November 21, 2011, reporting a corporate governance event that occurred on the same date. The filing addresses the election of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial details provided relate to director compensation:
- Stock Options: 30,000 shares granted to the new director.
- Exercise Price: $0.28 per share (closing price on November 21, 2011).
- Director Retainer: Pro-rated portion of a $20,000 annual retainer.
Material Changes
The primary material change reported is the appointment of Matthew Duffy as a director to fill a vacancy identified by the Nominating and Corporate Governance Committee. He was elected to serve until the 2012 annual meeting of stockholders.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. It strictly reports the procedural details of the director election and the associated compensatory arrangements under the Company's Amended and Restated 2006 Stock Incentive Plan.
Key Facts for Investor Verification
- Matthew Duffy was elected to the Board of Directors on November 21, 2011.
- Mr. Duffy received an initial grant of 30,000 stock options with a 10-year term, fully vesting on the grant anniversary.
- The option exercise price was set at $0.28 per share.
- A press release announcing this election was issued on November 28, 2011 (Exhibit 99.1).